Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Zealand to outline pros and cons of prostate cancer testing in new guidelines:

This article was originally published in Clinica

Executive Summary

New Zealand is to outline the pros and cons of the prostate specific antigen (PSA) diagnostic blood test in a new guidance document to be developed early next year. Currently, New Zealand does not recommend routine screening without symptoms. Along with other countries such as the US it has found that the test is not 100% accurate. It may miss some cancers or detect some slow-growing prostate cancers, which may not prove life threatening, in which case detection results in unnecessary anxiety, further tests or treatment that may be harmful or uncomfortable. The advice, to be jointly developed by the Prostate Cancer Foundation and the ministry of health, will enable patients and doctors to make an informed decision on whether to undergo a test or not.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel